Overview

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Status:
Withdrawn

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).

Phase:

Phase 3

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.
SecuraBio

Treatments:

Bendamustine Hydrochloride
Rituximab